Drug Profile
Research programme: anti-C5a immunotherapies - Resistentia Pharmaceuticals
Latest Information Update: 16 Oct 2014
Price :
$50
*
At a glance
- Originator Resistentia Pharmaceuticals
- Class
- Mechanism of Action Complement C5a inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Crohn's disease; Rheumatoid arthritis
Most Recent Events
- 16 Oct 2014 Discontinued - Preclinical for Crohn's disease in Sweden (unspecified route)
- 16 Oct 2014 Discontinued - Preclinical for Rheumatoid arthritis in Sweden (unspecified route)
- 29 Nov 2005 Preclinical trials in Crohn's disease in Sweden (unspecified route)